Saratov JOURNAL of Medical and Scientific Research

Urolithiasis: modern concepts of etiology of disease (review)


Urolithiasis is a polyetiological disease that occupies an important place in the practice of urologist. In the treatment of urolithiasis, the main approach is a search for the cause of disease and competent correction of existing disorders. It is especially important to know the etiology and risk factors of urolithiasis, which is the subject of this literature review. In this article, we look at inhibitors of stone formation, genetic aspects of the disease, risk factors in detail (bariatric surgery, inflammatory bowel disease, colonization of the intestine by Oxalobacter formigenes, renal SLC26A6 expression), relationship between urolithiasis and vitamin D. To review the literature, a search was performed in electronic databases, such as eLIBRARY, Embase, MEDLINE, Scopus, Web of Science, from January 1, 2000 to April 1, 2020, which considered the etiology and risk factors of urolithiasis. For the search, we used keywords and their combinations: "urolithiasis", "risk factors", "etiology". A total of 49 literature sources were analyzed.

1. Turk С, Neisius A, Petrik A, et al. EAU Guidelines on urolithiasis. European Association of Urology 2020; 87.
2. Lopatkin NA, Kamalov AA, Apolikhin Ol, et al. Urology. Moscow: GEOTAR-Media, 2013; 816 p.
3. Kamalov AA, Okhobotov DA, Nizov AN, et al. The role of inducing factors in the formation of Rendall plaques and the development of urolithiasis 2018; 164(9): 10-3.
4. Derevianko Tl, Bobrovsky Tl. Gender characteristics of urolithiasis. Materials of the congress. XIX Congress of the Russian Society of Urology (September 19-21, Rostov-on-Don) 2019; p. 175.
5. Apolikhin Ol, Sivkov AV, Komarova VA, et al. The incidence of urolithiasis in the Russian Federation (2005-2016). Materials of the Congress. XIX Congress of the Russian Society of Urology (September 19-21, Rostov-on-Don) 2019; pp. 198-9.
6. Goloshchapov ET, Chetverikov AV. Mass of the urinary microbiome in recurrent urolithiasis. Materials of the congress. XIX Congress of the Russian Society of Urology (September 19-21, Rostov-on-Don) 2019; pp. 180-1.
7. Alyaev YuG, Glybochko PV, Pushkar DYu. Urology. Russian clinical guidelines. Moscow: GEOTAR-Media, 2015; 480 p.
8. Saenko VS. Therapy of uric acid nephrolithiasis in the practice of a general practitioner and family doctor. RMJ. Medical Review 2018; (11): 45-8.
9. Chugunova OL, Shumikhina MV, Pavlushkina LV, et al. The main risk factors for the development of urolithiasis in children. Pediatrics. Journal named after G.N. Speransky 2018; 97 (5): 93-103.
10. Sergeeva TV, Kartamysheva NN. Diagnostic aspects of nephrolithiasis and nephrocalcinosis. Diagnostic Issues in Pediatrics 2009; 1 (4): 20-3.
11. DorofeevAE, Rudenko NN, Derkach IA, et al. Diseases of the intestines and kidneys. Gastroenterology 2015; 57 (3): 101-5.
12. Prosyannikov MY, Golovanov SA, Konstantinova OV, et al. Study of the problem of urolithiasis at the Institute of Urology: history, present and prospects. Experimental & Clinical Urology 2019; (1): 70-6.
13. Mikheeva NM, Zverev JF, Vykhodtseva Gl, et al. Modern concepts of the etiology and pathogenesis of idiopathic hypercalciuria. Nephrology 2015; 19 (4): 29-40.
14. Verkoelen CF. Crystal retention in renal stone disease: A crucial role for the glycosaminoglycan hyaluronan? J Am Soc Nephrol2006; (17): 1673-87.
15. Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Intern 2001; (60): 77-82.
16. YakushevNN, Madonov PG.Atabaeva OSh. Biochemical markers of renal tissue damage in experimental oxalate nephrolithiasis. Bulletin of Medical Science 2018; 11 (3): 19-23.
17. Prosyannikov MY, Golovanov SA. The functional state of cell membranes in patients with urolithiasis (Urolithiasis). Materials of the congress. XIX Congress of the Russian Society of Urology (September 19-21, Rostov-on-Don) 2019; p. 184.
18. Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models and t (-culture studies. Clin Exp Nephrol 2004; 8 (2): 75-88.
19. Khan SR. Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 2005; 33 (5): 349-57.
20. Gkentzis A, Kimuli M, Cartledge J, et al. Urolithiasis in inflammatory bowel disease and bariatric surgery. World journal of nephrology 2016; 5 (6): 538-46.
21. Hess B. Metabolic syndrome, obesity and kidney stones. Arab journal of urology 2012; 10 (3): 258-64.
22. Kumar R. Fat malabsorption and increased intestinal oxalate absorption are common after roux-en-Y gastric bypass surgery. Surgery 2011; 149 (5): 654-61.
23. Maalouf NM, Tondapu P, Guth ES, et al. Hypocitraturia and hyperoxaluria after Roux-en-Y gastric bypass surgery. The journal of urology 2010; 183 (3): 1026-30.
24. Siener R, Bangen U, Sidhu H, et al. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int 2013; 83 (6): 1144-49.
25. Gaspar SR, Mendonca T. Urolithiasis and Crohn's disease. Urology annals 2016; 8 (3): 297-304.
26. Helvaci MR, Algin MC, Kaya H. Irritable bowel syndrome and chronic gastritis, hemorrhoid, urolithiasis. Eurasian J Med 2009; 41 (3): 158-61.
27. Jiang H, Pokhrel G, Chen Y et al. High expression of SLC26A6 in the kidney may contribute to renal calcification via an SLC26A6-dependent mechanism. Peer J 2018; (6): 5192.
28. Svetlichnaya DV, Litvinova MM. Molecular genetic panel in assessing susceptibility to urolithiasis. Materials of the congress. XIX Congress of the Russian Society of Urology (September 19-21, Rostov-on-Don) 2019; p. 195.
29. Dimke Н, Desai Р, Borovac J, et al. Activation of the Ca (2+) — sensing receptor increases renal claudin-14 expression and urinary Ca (2+) excretion. Physiol Renal Physiol 2012; (304): 761-69.
30. Baltzegar DA, Reading BJ, Brune ES, Borski RJ. Phylogenetic revision of the claudin gene family. Marine Genomics2013; (11): 17-26.
31. Kausalya PJ, Amasheh S, Gunzel D, et al. Disease-associated mutations affect intracellular traffic and paracellular Mg2+ transport function of Claudin-16. The Journal of Clinical Investigation 2006; 166 (4): 878-91.
32. Muller D, Kausalya J. Unusual clinical presentation and possible rescue of a novel claudin-16 mutation. The Journal of Clinical Endocrinology & Metabolism 2006; 91 (8): 3076-9.
33. Rendina D, Mossetti G, Viceconti R, et al. Association between vitamin D receptor gene polymorphisms and fasting idiopathic hypercalciuria in recurrent stone-forming patients. Urology 2004; 64 (4): 833-8.
34. Zharikov AY, Zverev JF, Bryukhanov VM, Lampatov VV Modern concepts of modulators of oxalate nephrolithiasis. I. Stimulants of crystallization. Nephrology 2009; 13 (1): 56-72.
35. Dion М, Ankawi G, Chew В, et al. CUA guideline on the evaluation and medical management of the kidney stone patient — 2016 update. Assoc J 2016; 10 (11 -12): 347-58.
36. Maltsev SV, Mikhailova TV. Genetic and clinical aspects of nephrolithiasis and nephrocalcinosis in children with hypercalciuria. Pediatrics 2014; 9 (85): 118-25.
37. Zhu М, Tan Z, Luo Z, et al. Association of the vitamin D metabolism gene GC and CYP27B1 polymorphisms with cancer susceptibility: a meta-analysis and trial sequential analysis. Bioscience reports 2019; 39 (9): 1-13.
38. Royuk RV, Yarovoy SK, Guseva NA, etal. Epidemiological aspects of the combination of nephrolithiasis and chronic diseases of the cardiovascular system. Research and Practice in Medicine Journal 2020; 7 (1): 38-47.
39. Akoudad S, Szklo М. Correlates of kidney stone disease differ by race in a multi-ethnic middle-aged population: The ARIC study. Preventive Medicine 2010; 51 (5): 416-20.
40. Aviram M. Atherosclerosis: cell biology and lipoproteins — paraoxonases protect against atherosclerosis and diabetes development. Lipidol 2012; 23 (2): 169-71.
41. Lin SK, Liu JM, Chang YH, et al. Increased risk of endotracheal intubation and heart failure following acute myocardial infarction in patients with urolithiasis: a nationwide population-based study. Ther Clin Risk Manag 2017; (13): 245-53.
42. Demidko LS, Rudenko VI, Demidko LS, Kuzmicheva GM. Influence of osteoporosis and factors of its occurrence on the prevention of recurrence of urolithiasis. Urology 2019; (4): 26-31.
43. Kozyrakis D, Paridis D, Karatzas A, et al. Do Calcium Supplements Predispose to Urolithiasis? Current Urology Reports 2017; 18(3): 17.
44. Gunes S, Bilen CY, Kara N, et al. Vitamin D receptor gene polymorphisms in patients with urolithiasis. Urological Research 2006; (34): 47-52.
45. Filippova TV, Rudenko VI. Genetic aspects of primary hyperoxaluria: epidemiology, etiology, pathogenesis and clinical manifestations. Bulletin of the Russian Society of Urology 2019; (3): 24-5.
46. Alexander RT. Hereditary distal renal tubular acidosis. Gene Reviews [Internet] 2019. URL: https:// of the application —10.06.2020).
47. Glybochko PV, Nikolenko VN, Osnovin OV, Fomkin RN. Influence of the somatotype of patients with urolithiasis on the structure and severity of complications of remote lithotripsy. Russian medical and biological Bulletin named after academician I. P. Pavlov 2007; 15 (3): 83-7.
48. Osnovin OV, Popkov VM, Fomkina OA. The influence of premorbid background on the course of urolithiasis. Saratov Journal of Medical Scientific Research 2017; 13 (2): 280-3.
49. Osnovin OV, Popkov VM, Fomkina OA. The relationship between the characteristics of the premorbid background and the duration of remission of stone excretion in patients with urolithiasis. Innovative technologies in fundamental, clinical and preventive medicine: a collection of scientific papers of the Saratov State Medical University n. a. V I. Razumovsky. Saratov: Amirit; 2018: p. 88-90.

2020_03_773-779.pdf366.49 KB

No votes yet